Roflumilast
(Redirected from Daliresp)
Roflumilast[edit | edit source]
Roflumilast is a phosphodiesterase-4 inhibitor used as an anti-inflammatory agent in the treatment of chronic obstructive pulmonary disease (COPD). It is marketed under the brand name Daliresp, among others. Roflumilast is specifically indicated to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.
Mechanism of Action[edit | edit source]
Roflumilast works by inhibiting the enzyme phosphodiesterase-4 (PDE4), which leads to an increase in intracellular cyclic adenosine monophosphate (cAMP) levels. The elevation of cAMP results in a broad range of anti-inflammatory effects, including the suppression of the release of pro-inflammatory cytokines and the inhibition of inflammatory cell infiltration into the lungs. This mechanism helps to reduce the chronic inflammation associated with COPD.
Pharmacokinetics[edit | edit source]
Roflumilast is administered orally and is well absorbed from the gastrointestinal tract. It undergoes extensive metabolism in the liver, primarily by the cytochrome P450 enzymes CYP3A4 and CYP1A2, to form its active metabolite, roflumilast N-oxide. The drug and its metabolites are excreted mainly via the urine.
Clinical Use[edit | edit source]
Roflumilast is used as a maintenance treatment to reduce the frequency of exacerbations in patients with severe COPD. It is not a bronchodilator and should not be used for the relief of acute bronchospasm. The drug is typically prescribed to patients who have a history of frequent exacerbations despite the use of long-acting bronchodilators.
Side Effects[edit | edit source]
Common side effects of roflumilast include diarrhea, weight loss, nausea, headache, and insomnia. Some patients may experience psychiatric symptoms such as anxiety, depression, and insomnia. Due to the potential for weight loss, regular monitoring of body weight is recommended during treatment.
Contraindications and Precautions[edit | edit source]
Roflumilast is contraindicated in patients with moderate to severe liver impairment. Caution is advised when prescribing roflumilast to patients with a history of depression or suicidal thoughts. It is important to monitor patients for any changes in mood or behavior.
==
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD